Qingyi Zhu

Dr. Qingyi Zhu


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Cellular Signalling
Verified
Journal Article
Closed access
ZJZuolei Jing
Zuolei Jing
QLQianmei Liu
Qianmei Liu
WXWanlin Xie
Wanlin Xie
YWYong Wei
Yong Wei
JLJiale Liu
Jiale Liu
PLPing Liu
Ping Liu

13 March 2024 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
CZChao Zhang
Chao Zhang
ZWZheng Wang
Zheng Wang
TJTaile Jing
Taile Jing
YWYong Wei
Yong Wei
FGFei Guo
Fei Guo
LWLinhui Wang
Linhui Wang
Objective: To investigate the safety and feasibility of using a novel purpose-built single-port robotic system (the SHURUI Robotic Surgical System) with deformable surgical instruments to perform retroperitoneal single-port partial nephrectomy. Materials and methods: A prospective study was conducted to recruit patients with a single renal tumor no more than 4 cm. Robot-assisted single-port partial nephrectomy was performed by using the novel purpose-built single-port robotic system with deformable surgical instruments. Patients’ demographics, tumor characteristics, and perioperative parameters were recorded and analyzed. Results: Sixteen patients were recruited to the study. The median tumor size was 2.0 cm (IQR: 1.2–2.4 cm). The median R.E.N.A.L score was 6 (IQR: 4–4.5). In 3 cases, pure single-port surgery was carried out, and all the assistance was through the robotic port. Median docking time was 15.5 min (IQR: 14.25–22.25 min). Median operating time was 148.5 min (IQR: 178–238.5 min). Median console time was 107 min (IQR: 92.75–149.75 min). Median warm ischemic time was 26.5 min (IQR: 24.5–30 min). Median blood loss was 17.5 ml (IQR: 10–50 ml). Conclusions: Retroperitoneal partial nephrectomy can be safely performed with this novel purpose-built single-port robotic system (SHURUI) with deformable surgical instruments. Further studies are needed to fully evaluate the role of this new platform.

27 April 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
HWHongxi Wu
Hongxi Wu
LYLinjun You
Linjun You
YLYan Li
Yan Li
ZZZhili Zhao
Zhili Zhao
GSGuangjiang Shi
Guangjiang Shi
YYYong Yang
Yong Yang
In incurable castration-resistant prostate cancer (CRPC), resistance to the novel androgen receptor (AR) antagonist enzalutamide is driven mainly by AR overexpression. Here we report that the expression of interferon regulatory factor 8 (IRF8) is increased in primary prostate cancer but decreased in CRPC compared with normal prostate tissue. Decreased expression of IRF8 positively associated with CRPC progression and enzalutamide resistance. IRF8 interacted with AR and promoted its degradation via activation of the ubiquitin/proteasome systems. Epigenetic knockdown of IRF8 promoted AR-mediated prostate cancer progression and enzalutamide resistance in vitro and in vivo. Furthermore, IFNα increased expression of IRF8 and improved the efficacy of enzalutamide in CRPC by targeting the IRF8–AR axis. We also provide preliminary evidence for the efficacy of IFNα with hormonotherapy in a clinical study. Collectively, this study identifies IRF8 both as a tumor suppressor in prostate cancer pathogenesis and a potential alternative therapeutic option to overcome enzalutamide resistance. Significance: These findings identify IRF8-mediated AR degradation as a mechanism of resistance to AR-targeted therapy, highlighting the therapeutic potential of IFNα in targeting IRF8–AR axis in CRPC.

1 November 2016 in Cancer Letters
Verified
Journal Article
Closed access
PDF file
HWHongxi Wu
Hongxi Wu
LZLulu Zhang
Lulu Zhang
XGXiaofang Gao
Xiaofang Gao
XZXiuna Zhang
Xiuna Zhang
JDJingjing Duan
Jingjing Duan
YYYong Yang
Yong Yang

18 August 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
SJSilin Jiang
Silin Jiang
YDYuxiang Dong
Yuxiang Dong
JWJun Wang
Jun Wang
XZXi Zhang
Xi Zhang
WLWei Liu
Wei Liu
QZQingyi Zhu
Qingyi Zhu
Background: Immunogenic cell death (ICD) is considered a particular cell death modality of regulated cell death (RCD) and plays a significant role in various cancers. The connection between kidney renal clear cell carcinoma (KIRC) and ICD remains to be thoroughly explored.Methods: We conducted a variety of bioinformatics analyses using R software, including cluster analysis, prognostic analysis, enrichment analysis and immune infiltration analysis. In addition, we performed Quantitative Real-time PCR to evaluate RNA levels of specific ICD genes. The proliferation was measured through Cell Counting Kit-8 (CCK-8) assay and colony-formation assay in RCC cell lines. Results: We determined two ICD subtypes through consensus clustering analysis. The two subtypes showed significantly different clinical outcomes, genomic alterations and tumor immune microenvironment. Moreover, we constructed the ICD prognostic signature based on TF, FOXP3, LY96, SLC7A11, HSP90AA1, UCN, IFNB1 and TLR3 and calculated the risk score for each patient. Kaplan-Meier survival analysis and ROC curve demonstrated that patients in the high-risk group had significantly poorer prognosis compared with the low-risk group. We then validated the signature through external cohort and further evaluated the relation between the signature and clinical features, tumor immune microenvironment and immunotherapy response. Given its critical role in ICD, we conducted further analysis on LY96. Our results indicated that downregulation of LY96 inhibited the proliferation ability of RCC cells.Conclusions: Our research revealed the underlying function of ICD in KIRC and screened out a potential biomarker, which provided a novel insight into individualized immunotherapy in KIRC.

30 September 2021 in The Prostate
Verified
Journal Article
Closed access
PDF file
YYYingying Yin
Yingying Yin
QLQianmei Liu
Qianmei Liu
YSYingying Shao
Yingying Shao
XHXinyuan He
Xinyuan He
QZQingyi Zhu
Qingyi Zhu
PLPing Liu
Ping Liu